Piñero F, et al. - Since data from Europe and North America have been published regarding the risk of developing hepatocellular carcinoma (HCC) after treatment with direct antiviral agents (DAA), researchers proposed to assess the cumulative incidence and associated risk factors for de novo HCC using Cox proportional regression models. Participants in the study were 1400 F1-F4-treated patients with DAAs. According to this prospective multicentre cohort study from Latin America, the cumulative incidence of HCC in cirrhotic patients was 0.03 at 12 months and 0.06 at 24 months of follow-up. Findings suggested that achieving SVR with DAA regimens was related to a significant reduction in HCC risk. In patients with advanced fibrosis, however, this risk remained high, requiring continuous surveillance strategies in this population.